Biocatalytic synthesis of intermediates for the synthesis of chiral drug substances.
There has been an increasing awareness of the enormous potential of microorganisms and enzymes for the transformation of synthetic chemicals with high chemo-, regio- and enantioselectivity. Chiral intermediates and fine chemicals are in high demand, both from the pharmaceutical and agrochemical industries, for the preparation of bulk drug substances and agricultural products. Biocatalytic processes have been described for the synthesis of chiral intermediates for beta3- and beta2-receptor agonists, antihypertensive drugs, antiviral agents, melatonin receptor agonists, anticholesterol and anticancer drugs, and drugs to treat Alzheimer's disease.
Patel
R N
RN
Process Research and Development, Bristol-Myers Squibb Pharmaceutical Research, Institute New Brunswick, Brunswick, New Jersey 08903, USA. patelr@bms.com
D058666:Adrenergic beta-2 Receptor Agonists; D058667:Adrenergic beta-3 Receptor Agonists; D000924:Anticholesteremic Agents / Q000138:chemical synthesis; D000959:Antihypertensive Agents / Q000138:chemical synthesis; D000970:Antineoplastic Agents / Q000138:chemical synthesis; D000998:Antiviral Agents / Q000138:chemical synthesis; D001709:Biotechnology / Q000379:methods*; D002384:Catalysis; D004345:Drug Industry / Q000379:methods*; D004791:Enzyme Inhibitors / Q000138:chemical synthesis; D006801:Humans; D007700:Kinetics; D008956:Models, Chemical; D009646:Norleucine / Q000138:chemical synthesis; D004364:Pharmaceutical Preparations / Q000138:chemical synthesis*; D010649:Phenylalanine / Q000737:chemistry
D058666:Adrenergic beta-2 Receptor Agonists; D058667:Adrenergic beta-3 Receptor Agonists; D000924:Anticholesteremic Agents; D000959:Antihypertensive Agents; D000970:Antineoplastic Agents; D000998:Antiviral Agents; D004791:Enzyme Inhibitors; D004364:Pharmaceutical Preparations; D010649:Phenylalanine; D009646:Norleucine